Hürthle cell adenoma

Hürthle cell adenoma is a rare type of benign tumor that arises from the Hürthle cells in the thyroid gland. These cells, also known as oxyphil cells, are characterized by their distinct large size, abundant granular cytoplasm, and deeply staining nuclei. Hürthle cell adenomas are classified under the broader category of follicular adenoma of the thyroid, but they are distinguished by their unique cellular composition. Although benign, these tumors can present challenges in diagnosis and management due to their potential to mimic more aggressive forms of thyroid cancer.

Epidemiology

Hürthle cell adenomas are relatively uncommon, accounting for about 3% of all solitary thyroid nodules. They can occur at any age but are most frequently diagnosed in individuals between the ages of 30 and 50. There is a slight predilection for females over males.

Pathophysiology

The exact cause of Hürthle cell adenoma remains unclear. However, it is believed that genetic mutations, radiation exposure, and certain environmental factors may play a role in the development of these tumors. Hürthle cells themselves are a variant of follicular cells in the thyroid gland, and when they proliferate abnormally, they can form a Hürthle cell adenoma.

Clinical Presentation

Patients with Hürthle cell adenoma typically present with a solitary thyroid nodule. These nodules are usually asymptomatic and are often discovered incidentally during a physical examination or imaging studies performed for unrelated reasons. In some cases, patients may experience symptoms related to the compression of adjacent structures in the neck, such as difficulty swallowing or breathing.

Diagnosis

The diagnosis of Hürthle cell adenoma involves a combination of clinical evaluation, imaging studies, and histopathological examination. Ultrasound of the thyroid is commonly used to assess the characteristics of the nodule. Fine-needle aspiration biopsy (FNAB) is a critical diagnostic tool that allows for the cytological examination of cells obtained from the nodule. However, distinguishing Hürthle cell adenoma from Hürthle cell carcinoma based solely on cytology can be challenging, and in many cases, surgical excision of the nodule is required for definitive diagnosis.

Treatment

The primary treatment for Hürthle cell adenoma is surgical removal of the tumor. Depending on the size of the tumor, the patient's clinical status, and the presence of other thyroid pathology, the extent of surgery may vary from lobectomy (removal of one lobe of the thyroid) to total thyroidectomy (removal of the entire thyroid gland). Postoperative monitoring is essential to detect any recurrence or development of new nodules.

Prognosis

The prognosis for patients with Hürthle cell adenoma is generally excellent, as these tumors are benign and have a low risk of recurrence after complete surgical excision. Regular follow-up with physical examinations and thyroid function tests is recommended to monitor thyroid health and detect any changes early.

See Also

• Thyroid nodule
• Follicular adenoma
• Thyroid cancer
• Fine-needle aspiration

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian